Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event

BACKGROUND: There is no specific serum-based biomarker for the diagnosis or prognosis of relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: We investigated whether levels of IgM antibodies to Glc(α1,4)Glc(α) (GAGA4) or to a panel of four glucose-based glycans could differentiate MS from other...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, MS, Laks, J, Dotan, N, Altstock, RT, Dukler, A, Sindic, CJM
Formato: Texto
Lenguaje:English
Publicado: SAGE Publications 2009
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850589/
https://www.ncbi.nlm.nih.gov/pubmed/19324980
http://dx.doi.org/10.1177/1352458508101944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850589/
https://www.ncbi.nlm.nih.gov/pubmed/19324980
http://dx.doi.org/10.1177/1352458508101944

Ejemplares similares